Clinical Trial Update: Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) [Phase 3]

View source ↗

Summary

Phase 3 trial update on ferric carboxymaltose for iron deficiency anemia in non-dialysis-dependent chronic kidney disease. Results were posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Iron Deficiency Anemia

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: Vifor Pharma | Conditions: Iron Deficiency Anaemia, Chronic Kidney Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-05-07